Calamos Wealth Management LLC Purchases 1,269 Shares of Stryker Corporation $SYK

Key Points

• Calamos Wealth Management LLC increased its holdings in Stryker Corporation by 3.8% in the 2nd quarter, owning a total of 34,821 shares valued at approximately $13.8 million.
• Analysts have generally rated Stryker stock positively, with an average rating of "Moderate Buy" and a target price of $431.76.
• Stryker recently announced a quarterly dividend of $0.84 per share, representing an annualized yield of 0.9%.

Calamos Wealth Management LLC raised its position in Stryker Corporation (NYSE:SYK - Free Report) by 3.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 34,821 shares of the medical technology company's stock after purchasing an additional 1,269 shares during the period. Calamos Wealth Management LLC's holdings in Stryker were worth $13,776,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Consolidated Portfolio Review Corp boosted its holdings in Stryker by 4.2% in the 2nd quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company's stock valued at $256,000 after purchasing an additional 26 shares during the period. Sunflower Bank N.A. raised its position in shares of Stryker by 4.0% during the 2nd quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company's stock valued at $275,000 after buying an additional 27 shares in the last quarter. Pitti Group Wealth Management LLC raised its position in shares of Stryker by 3.2% during the 2nd quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company's stock valued at $341,000 after buying an additional 27 shares in the last quarter. Sachetta LLC raised its position in shares of Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company's stock valued at $29,000 after buying an additional 27 shares in the last quarter. Finally, Comprehensive Financial Consultants Institutional Inc. raised its position in shares of Stryker by 0.6% during the 2nd quarter. Comprehensive Financial Consultants Institutional Inc. now owns 4,546 shares of the medical technology company's stock valued at $1,799,000 after buying an additional 28 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Stryker from a "hold" rating to a "buy" rating in a research report on Saturday. Needham & Company LLC raised their price objective on shares of Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Evercore ISI lowered their price objective on shares of Stryker from $418.00 to $410.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 7th. Truist Financial lowered their price objective on shares of Stryker from $415.00 to $407.00 and set a "hold" rating on the stock in a research report on Wednesday. Finally, Redburn Partners set a $420.00 target price on shares of Stryker in a research report on Thursday, September 18th. Fifteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Stryker has an average rating of "Moderate Buy" and an average price target of $431.76.

Stryker Price Performance

Shares of Stryker stock opened at $374.67 on Friday. The firm has a market cap of $143.24 billion, a PE ratio of 49.63, a price-to-earnings-growth ratio of 2.70 and a beta of 0.94. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The company's fifty day simple moving average is $379.40 and its two-hundred day simple moving average is $378.77.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company's revenue was up 11.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, equities analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker's dividend payout ratio (DPR) is 44.50%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the sale, the director owned 3,222,108 shares of the company's stock, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. The trade was a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.